Nikotin
Synopsis
Nicotine, the primary psychoactive substance responsible for tobacco addiction, is an alkaloid derivative with high toxicity acting as a neurotransmitter agonist. By binding to neuronal nicotinic acetylcholine receptors (nAChRs)—predominantly the alpha-4 beta-2 subunit in the human brain—it induces neuronal depolarization and stimulates dopamine release in the mesolimbic area and corpus striatum. This mechanism reinforces reward pathways, whereas repeated nicotine exposure leads to receptor desensitization, neuroadaptation, tolerance, and withdrawal symptoms. Primarily metabolized in the liver by the CYP2A6 enzyme into cotinine and trans-3'-hydroxycotinine, nicotine possesses a half-life of 1–2 hours, whereas cotinine, preferred as a biomarker, has a half-life of 8–30 hours. Flavoring agents in electronic nicotine delivery systems, such as menthol and diacetyl, enhance total exposure and respiratory toxicity. Nicotine displays cross-tolerance with alcohol and morphine. Nicotine replacement therapy (NRT) serves as a first-line pharmacotherapy for smoking cessation via systemic venous absorption. Additionally, the therapeutic potential of nicotine is currently being investigated for neurological and psychiatric conditions, including Parkinson's disease, Alzheimer's disease, and schizophrenia.
References
Asma S, Mackay J, Song SY, et al., Global Tobacco Survey, The GATS Atlas. 2015. CDC Foundation, Atlanta, GA.Syf.:9. Erişim Tarihi: 22.06.2021, Erişim Linki: http://gatsatlas.org/downloads/GATS-whole-book-12.pdf
Kamboj A, Spiller HA, Casavant MJ, et al.. Pediatric exposure to e-cigarettes, nicotine, and tobacco products in the United States. Pediatrics, 2016;137(6). doi:10.1542/peds.2016-0041
Benowitz NL, Jacob P 3rd. 1999. Pharmacokinetics and metabolism of nicotine and related alkaloids. Stephen P. Arneric (Ed.), Jorge D. Brioni (Ed.). Neuronal Nicotinic Preceptors Pharmacology and Therapeutic Opportunities. Boston: Wiley-Liss, Inc. Pp.213–234.
Hogg RC, Bertrand D, Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors, Biochemical Pharmacology, Volume 73, Issue 4. 2007, Pages 459-468, ISSN 0006-2952, doi: 10.1016/j.bcp.2006.08.010
Picciotto MR, Zoli M, Changeux JP. Use of knockout mice to determine the molecular basis for the actions of nicotine. Nicotine & Tobacco Research .1999;1(Suppl 2):S121–5. doi: 10.1080/14622299050011931
Hubbs AF, Cumpston AM, Goldsmith † W Travis, Battelli LA, Kashon ML, Jackson MC, et al. Cardiovascular, Pulmonary, and Renal Pathology Respiratory and Olfactory Cytotoxicity of Inhaled 2,3-Pentanedione in Sprague-Dawley Rats. Am J Pathol [Internet]. 2012 [cited 2021 Jun 20];181(3). doi: 10.1016/j.ajpath.2012.05.021
El-Khoury JM, Wang S. Recent advances in MS methods for nicotine and metabolite analysis in human matrices: Clinical perspectives. Bioanalysis. 2014;6(16):2171–83. doi: 10.4155/bio.14.176
Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metabolism and Disposition. 2001; 29:548–552.
Cholerton S, Boustead C, Taber H, et al.. CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics 1996; 6:261–263. doi: 10.1097/00008571-199606000-00010
Saarikoski ST, Sata F, Husgafvel-Pursiainen K, et al.. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. Pharmacogenetics 2000; 10:5–10. doi: 10.1097/00008571-200002000-00002
Caporaso NE, Lerman C, Audrain J, et al.. Nicotine Metabolism and CYP2D6 Phenotype in Smokers, Cancer Epidemiology Biomarkers&Prevention. Prev March 1 2001 (10) (3) 261-263.
Akyüz F, Kara Y, Kar F ve ark.. Sigara Dumanına Maruz Kalan Sıçanlarda Lipit Profili ve Karaciğer Fonksiyon Testleri Üzerine L -NAME ve Vitamin E’ nin Etkileri. Osmangazi Journal of Medicine, 2019. 41(1), 39–45. doi: 10.20515/otd.426850
Lovlie R, Daly AK, Molven A, et al.. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Letters. 1996. Aug 19;392(1):30-4. PMID: 8769309. doi: 10.1016/0014-5793(96)00779-x
Zarrindast MR, Faraji N, Rostami P, et al. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacology Biochemistry Behavior. 2003 Jan;74(2):363-9. PMID: 12479956. doi: 10.1016/s0091-3057(02)01002-x
de Fiebre CM, Collins AC. A comparison of the development of tolerance to ethanol and cross-tolerance to nicotine after chronic ethanol treatment in long- and short-sleep mice. Journal of Pharmacology and Experimental Therapeutics. 1993. 266:1398–1406. PMID: 8371145
Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology, 2015. 96; 255–262. doi:10.1016/j.neuropharm.2014.11.018
Dondé C, Brunelin J, Mondino M, Cellard C, Rolland B, Haesebaert F. The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review. Neurosci Biobehav Rev. 2020 Nov;118:121-133. Epub 2020 Jul 30. PMID: 32739422. doi: 10.1016/j.neubiorev.2020.07.035
Kannichamy V, Antony I, Mishra V, et al.. Transdermal Nicotine as a Treatment Option for Ulcerative Colitis: A Review. Cureus. 2020 Oct 22;12(10):e11096. PMID: 33240692; PMCID: PMC7681756. doi: 10.7759/cureus.11096
Gandelman JA, Newhouse P, Taylor WD. Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression. Neuroscience & Biobehavioral Reviews. 2018 Jan;84:289-298. Epub 2017 Aug 30. PMID: 28859996; PMCID: PMC5729074. doi: 10.1016/j.neubiorev.2017.08.018
Quik M. Smoking, nicotine and Parkinson’s disease. Trends in Neurosciences. 2004. 27, 561–568. PMID: 15331239. doi: 10.1016/j.tins.2004.06.008